



# Veozah in the UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

IMMUNOLOGY · MODERATE-SEVERE VMS IN MENOPAUSE

## Clinical context

Veozah (fezolinetant) is an oral, selective neurokinin-3 (NK3) receptor antagonist developed by Astellas and FDA-approved for the treatment of moderate-to-severe vasomotor symptoms (hot flushes, night sweats) associated with menopause. The standard regimen is 45 mg once daily. Per FDA labelling, baseline liver function tests are required before initiation, with follow-up LFT monitoring at months 3, 6, and 9 to detect transaminase elevations. Veozah is a non-hormonal alternative for women for whom oestrogen therapy is contraindicated or undesirable.

## Access pathway — 5 steps

1. **Concierge consultation.** Intake of your menopausal-symptom profile, cardiovascular and hepatic history, prior hormone therapy, and UAE residency documentation.
2. **Baseline workup.** Menopausal-symptom severity scoring, LFT panel (ALT, AST, alkaline phosphatase, bilirubin), and reconciliation with any contraindicated concomitant medications.
3. **MoHAP named-patient application.** Treating physician files the named-patient dossier with the UAE Ministry of Health and Prevention; Reserve Meds prepares the US-side DSCSA chain-of-custody packet.
4. **US-side sourcing.** Authorised-distributor procurement from Astellas supply, sealed controlled-ambient packaging, full pedigree documentation, and IOR-of-record customs clearance into the UAE.
5. **Arrival & first dose.** Courier handoff at your clinic or residence, first-dose confirmation, and scheduling of month-3 LFT follow-up per protocol.

INDICATIVE ECONOMICS

**USD 600–700 per month of  
Veozah**

TIMING, FIRST SHIPMENT

**7–14 days from dossier complete**

## What Reserve Meds does

**Sourcing** from authorised US distributors with full Astellas pedigree. **Documentation** — MoHAP named-patient dossier coordination alongside your treating physician. **Logistics** — controlled-ambient sealed-packaging transit with IOR-of-record customs clearance. **Concierge case lead** — one named coordinator from

consultation through arrival and month-3 LFT follow-up. We are a coordinator, not a prescriber; all clinical decisions remain with your treating physician and the MoHAP-issued import authorisation.

*reserved for you.*

**Join the Veozah × UAE first-cohort waitlist.**

[reservemed.com/access-guides/veozah-uae.html](https://reservemed.com/access-guides/veozah-uae.html)



Reserve Meds is a cross-border specialty-medicine coordinator, not a prescriber, pharmacy, or regulator. All therapies are supplied through authorised US distributors and imported under the destination country's named-patient / personal-import framework with the treating physician's prescription and regulator authorisation. Indicative economics and timing are estimates, not quotes. No controlled substances. Export from US only.

WhatsApp concierge: +1 516 528 3120 · [reservemed.com](https://reservemed.com) · Reviewed 2026-04-23